FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:33:192 | Hand Microvascular Damage Is Associated with Hand Bone Loss in Systemic Sclerosis Rosanna Campitiello1|3, Sabrina Paolino1|2, Andrea Casabella1|2, Giulia Davoli1|2, Elisa Caratto1|2, Emanuele Gotelli1|2, Elvis Hysa1|2, Carmen Pizzorni1|2, Vanessa Smith4|5, Alberto Sulli1|2, Maurizio Cutolo1|2 | 11. Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medic Genova, Italy; 2IRCCS Ospedale Policlinico San Martino Genova, Italy; 3Department of Experimental Medicine DIMES, University of Genova Genova, Italy; 4Department of Internal Medicine and Department of Rheumatology, Ghent University Hospital Ghent, Belgium; 5Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Centre, Ghent, Belgium
81 -
PO:06:094 | Exploring the relationship between inflammation and collagen deposition in synovial tissue and clinical outcomes in active arthritis: insights from a monocentric pilot study Dario Bruno1, Barbara Tolusso1, Daniela Renna1, Mohamed Hegazi2, Fabio Pasqualini2, Marta Caprioli1, Giacomo Maria Guidelli1, Tommaso Hubert3, Nicoletta Luciano1|3, Marzia Monferini3, Natasa Isailovic3, Fabio Grizzi2|3, Salvatorelorenzo Renne3, Costantino Pitzalis1|3|4, Elisa Gremese1|3. | 1Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI); 2Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Milano; 3Department of Biomedical Sciences, Humanitas University, Rozzano (MI), Italy; 4Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, UK
199 -
PO:01:011 | Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies Lianne S Gensler1, Helena Marzo-Ortega2, Vanessa Taieb3, Diana Voiniciuc4, Alexander Marten5, George Stojan6, Mindy Kim6, Paolo Marsico7, Martin Rudwaleit8 | 1Department of Medicine/Rheumatology, University of California San Francisco, USA; 2NIHR Leeds Biomedical Research Centre, University of Leeds Leeds, United Kingdom; 3UCB Colombes, France; 4UCB Slough, United Kingdom; 5UCB Monheim am Rhein Germany; 6UCB Atlanta, USA; 7UCB Milan, Italy; 8University of Bielefeld, Klinikum Bielefeld Bielefeld Germany
75 -
PO:18:268 | Voclosporin as a Steroid-Sparing Agent in Lupus Nephritis Complicated by Central Serous Chorioretinopathy: A Case Report Irene Genovali1|2, Sebastiano Lorusso2, Damiano Currado1|2, Letizia Pia Di Corcia1, Ludovica Lamberti1, Annalisa Marino2, Antonio Orlando1, Maria Quadrini1, Marta Vadacca2, Marta Vomero1, Luca Navarini1|2, Roberto Giacomelli1|2 | 1Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine Rome, Italy; 2Clinical and Research Section of Rheumatology and Clinical Immunology Fondazione Policlinico Campus Biomedico Rome, Italy
180 -
CO:08:5 | Clinical impact of anti-Ro52 antibodies in idiopathic inflammatory myopathies: insights from a multicenter Italian cohort Paola Bizioli1, Cesare Tomasi2, Francesca Bellisai3, Francesca Buzzulini4, Antonio Tonutti5|6, Angela Ceribelli5|6, Edoardo Conticini3, Anna Ghirardello7, Luca Iaccarino7, Danilo Villalta4, Franco Franceschini1, Ilaria Cavazzana1. | 1Rheumatology and Clinical Immunology Unit - ERN ReCONNET, ASST Spedali Civili of Brescia; 2Department of Clinical and Experimental Sciences, University of Brescia; 3Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena; 4Department of Laboratory Immunology and Allergology, Santa Maria degli Angeli Hospital, Pordenone; 5Department of Biomedical Sciences, Humanitas University, Rozzano (MI); 6Rheumatology and Clinical Immunology, Istituti di Ricovero e Cura a Carattere Scientifico, Humanitas Research Hospital, Rozzano (MI); 7Division of Rheumatology, Department of Medical and Surgical Sciences, University of Padova, Italy
261 -
PO:25:083 | Overlap between Sjögren’s syndrome and lichen sclerosus: beyond coincidence? Emanuele Giovanni Grilli1, Ludovica Manisera1, Ilenia Fischetti1, Linda Mastromanno1, Martina Villa1, Angelica Gattamelata1, Fabrizio Conti1, Roberta Priori1|2, Serena Colafrancesco3|4 | 1Dipartimento di Medicina e Chirurgia, Università Milano-Bicocca; 2U.O. Reumatologia, IRCCS Fondazione San Gerardo dei Tintori, Monza; 3U.O. Pneumologia, IRCCS Fondazione San Gerardo dei Tintori, Monza; 4Rheumatology and Clinical Immunology, Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS Humanitas Research Hosp, Rozzano, Milano, Italy
352 -
PO:01:003 | Sex-based differences in 2 years treatment outcomes with b/ts-DMARDs in psoriatic arthritis: from real-world evidence to predictive modeling from the Gruppo Italiano Studio Early Arthritis (GISEA) prospective registry Simone Perniola1, Florenzo Iannone1, Francesco Paolo Cantatore2, Angelo Semeraro3, Leonardo Santo4, Roberto Gorla5, Alberto Cauli6, Roberto Felice Caporali7, Bruno Frediani8, Rosario Foti9, Fabrizio Conti10, Marco Sebastiani11, Maria Sole Chimenti12, Roberta Ramonda13, Fabiola Atzeni14, Maurizio Rossini15, Serena Bugatti16, Serena Guiducci17, Giovanni Lapadula1, Gianfranco Ferraccioli18, Francesca Romana Spinelli10, Elisa Gremese19. | 1Rheumatology Unit, DiMePReJ, University of Bari, Bari; 2Rheumatology Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria Policlinico Riuniti, Foggia; 3Rheumatology Unit, Martina Franca Hospital; 4Rheumatology Unit, ASL BT, P.O. Barletta; 5Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia; 6Rheumatology Unit, Department of Medical Science and Public Health, University of Cagliari, Monserrato (CA); 7Rheumatology Unit, Dipartimento di Reumatologia e Scienze Mediche, ASST PINI-CTO, University of Milano, Milano; 8Rheumatology Unit, Azienda Ospedaliero Universitaria Senese, Siena; 9Rheumatology Unit, A.O.U. Policlinico S. Marco, Catania; 10Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and CV Sciences, Sapienza University of Rome, Roma; 11Rheumatology Unit, AUSL Piacenza, University of Parma, Parma; 12Rheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Roma; 13Rheumatology Unit, DIMED, University of Padua, Padova; 14Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina; 15Rheumatology Unit, Department of Medicine, University of Verona, Verona; 16Division of Rheumatology, Dept. of Internal Medicine and Therapy, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia; 17Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Firenze, Firenze; 18Department of Medicine, Catholic University of the Sacred Heart, Fondazione Policlinico Gemelli IRCCS, Roma; 19Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy
283 -
PO:32:182 | Disease characteristics of anti-centromere positive systemic sclerosis patients and risk factors for organ involvement: data from the EUSTAR cohort Corrado Campochiaro1, Jelena Colic2, Del Papa Nicoletta3, Oliver Distler4, Serena Guiducci5, Florenzo Iannone6, David Launay7, Yair Levy8, Britta Maurer9, Arsene Mekinian10, Predrag Ostojic2, Gabriela Riemekasten11, Petros Sfikakis12, Bojana Stamenkov13, Ulrich Walker14, Marie Elise Truchetet15, Madelon Vonk16, Francesco Del Galdo17, Giacomo De Luca1, Lorenzo Dagna1, Marco Matucci Cerinic1, Yannick Allanore18 | 1IRCCS San Raffaele Hospital; Vita Salute San Raffaele University Milan, Italy; 2University of Belgrade Belgrade, Serbia; 3UOC Reumatologia Clinica, ASST G. Pini CTO Milan, Italy; 4University Hospital Zurich Zurich, Switzerland; 5Department of Rheumatology, University of Florence Florence, Italy; 6Rheumatology Unit Bari, Italy; 7CHU Lille Lille, France; 8Department of Medicine Kfar Saba, Israel; 9Department for BioMedical Research, University of Bern Bern, Switzerland; 10Service de medecine interne Paris, France; 11Department of Rheumatology University of Lubeck Lubeck Germany; 12National and Kapodistrian University of Athens Athens, Greece; 13University School of Medicine, Nis Nis, Serbia; 14University Hospital Basel, Basel Basel, Switzerland; 15Bordeaux Hospital and University Bordeaux, France; 16Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 17Leeds Institute of Rheumatic and Muskuloskeletal Medicine Leeds, United Kingdom; 18Cochin Hospital Paris, France
282 -
PO:07:108 | Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study Enrico Marchetta1, Andrew Östör2|8, Eugen Feist3, Prodromos Sidiropoulos4, Jérôme Avouac5, Martin Rebella6|7, Rajaie Namas9, Erin Mcdearmon Blondell10, Ivan Lagunes10, Tianming Gao10, Tim Shaw10, Suzan Attar11 | 1AbbVie Srl Roma, Italy; 2Monash University and Emeritus Research, Melbourne, Victoria, Melbourne, Australia; 3Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Vogelsang Gommern, Germany; 4Faculty of Medicine, University of Crete, Heraklion, Heraklion, Greece; 5Service de Rhumatologie, Hôpital Cochin, AP HP Centre Université Paris Cité, Parigi, France; 6Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Montevideo, Uruguay; 7Unidad de Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Montevideo, Uruguay; 8Australian National University, Camberra, Australia; 9Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, United Arab Emirates; 10AbbVie Inc., North Chicago, Illinois, United States of America Chicago, USA; 11King Abdulaziz University, Jeddah, Saudi Arabia
91 -
PO:07:099 | Survival on therapy of certolizumab pegol in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: 8-year data from an Italian multicenter register Maria Manara1, Gilberto Cincinelli1|2, Marco Fornaro3, Simone Perniola4, Elisa Gremese5, Chiara Bazzani6, Serena Bugatti7, Francesca Romana Spinelli8, Rosario Foti9, Marco Sebastiani10, Alberto Cauli11, Fabiola Atzeni12, Giovanni Lapadula13, Gianfranco Ferraccioli14, Fabrizio Conti8, Florenzo Iannone3, Roberto Caporali1|2 | 1Department of Rheumatology and Medical Sciences, ASST G. Pini-CTO Milano; 2Department of Clinical Sciences and Community Health, University of Milan; 3Department of Precision and Regenerative Medicine and Ionian Area, University of Bari; 4Clinical Immunology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma; 5Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI); 6Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia; 7Department of Internal Medicine and Therapeutics, Università di Pavia; 8Rheumatology Unit, Dipartimento Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza University, Roma; 9Rheumatology Unit, San Marco Hospital, Policlinico University of Catania; 10Rheumatology Unit, AUSL Piacenza, University of Parma; 11UOC di Reumatologia, Dipartimento di Scienze Mediche e Sanità Pubblica, Azienda Ospedaliero-Universitaria di Cagliari; 12Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina; 13Gruppo Italiano di Studio sulla Early Arthritis, GISEA, Bari; 14Department of Medicine, Università Cattolica del Sacro Cuore, Fondazione IRCCS Policlinico Gemelli, Roma, Italy
294 -
PO:33:199 | Prevalence and clinical associations of antiphospholipid antibodies in patients with systemic sclerosis in the SPRING-SIR registry Antonio Tonutti1|2, Ilaria Cavazzana3, Angela Ceribelli1|2, Maria De Santis1|2, Giacomo De Luca4|5, Maria Grazia Lazzaroni3, Franco Franceschini3, Carlo Selmi1|2, Valeria Riccieri6, Silvia Laura Bosello7, Fabio Cacciapaglia8, Veronica Codullo9, Francesca Ingegnoli10, Dilia Giuggioli11, Rossella De Angelis12, Clodoveo Ferri11, Marco Matucci-Cerinic4|5 | 1Department of Biomedical Sciences, Humanitas Universityce Pieve Emanuele, Milan, Italy; 2Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 3Rheumatology and Clinical Immunology - ASST Spedali Civili Brescia - Department of Clinical and Experimental Sciences - Brescia, Italy; 4Vita-Salute San Raffaele University Milan, Italy; 5Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR and INFLAGE Initiative, IRCCS San Raffaele Hospital Milan, Italy; 6University of Rome La Sapienza Rome, Italy; 7Catholic University of Sacred Heart Rome, Italy; 8LUM University Bari, Italy; 9Rheumatology Unit, Fondazione IRCCS Policlinico San Matteo Pavia, Italy; 10University of Milan Milan, Italy; 11University of Modena and Reggio Emilia Modena, Italy; 12Politechnic University of Marche Ancona, Italy
65
